drugset / Trial / NCT04536454

Study to Assess Safety and PET Imaging Characteristics of a Novel Senescence-specific Radiotracer [18F]FPyGal (2-[Fluorine-18]Fluoro-3-pyridinyl-β-D-galactopyranoside)

NCT04536454 ↗

Phase 1/2 Unknown 32 enrolled University Hospital Tuebingen
NaSingle-groupOpen-labelDiagnostic

Summary

It is of particular interest to find out whether it is possible to use the novel radiotracer \[18F\]FPyGal to be tested to detect areas after standard tumor therapy that contain resistant (therapy-resistant) tumor cells. This resistance phenomenon in tumor tissues, which may be visualized with the radiotracer \[18F\]FPyGal, is called tumor senescence.

Timeline

Start
2021-04-28
Primary completion
2023-06
Completion
2024-06

Drugs

EvaluationDrugModalityDoseRoute
Subject [18F]FPyGal Diagnostic / imaging agent — Other

Indications